Decipher

Prostate Ca test influences decision-making post RP“From our results, the Decipher test helps reassure low-risk patients that observation may be warranted or confirm that high-risk patients need additional treatment,” says study author John L. Gore, MD, MSHS.
Biomarkers predict metastasis, biochemical recurrenceClinicians may soon be able to improve the risk stratification of men with prostate cancer with the help of a genomic classifier or a biopsy-based reverse transcription polymerase chain reaction assay, according to the results of two studies presented at the Genitourinary Cancers Symposium in Orlando, FL.
Test predicts PCSM at 10 years post prostatectomyNew research suggests that urologists can use the Decipher genetic test (GenomeDx Biosciences) to improve predictions of death risk from prostate cancer at10 years after prostatectomy.
Study: PCa genomic test reduces decisional conflictFor men with high-risk pathology at radical prostatectomy, exposure to results of a genomic test that classifies 5-year risk of metastasis reduces decisional conflict, according to findings of a prospective study presented at the American Society of Clinical Oncology annual meeting in Chicago.
Prostate cancer guidelines: A primer for urologistsFour current clinical practice guidelines on prostate cancer provide urologists with valuable, evidence-based decision points about diagnosis and treatment while raising questions that will likely be addressed by future research.
Markers redefining prostate cancer careIn this interview, Daniel W. Lin, MD, discusses the practical use of currently available molecular and genomic tests, cost and reimbursement considerations, the role of MRI, and what the future holds for biomarkers.
Data support PCa markers, but more study neededA leader in urologic oncology discusses four currently available molecular tests in this report from Urology Times SUO internship program member Brandon Manley, MD.
Biomarkers offer insight into PCa racial disparityA newly identified subset of prostate cancer biomarkers could help explain why African-American men are more likely than European-American men to develop and die from prostate cancer.
Biomarkers yet to fully justify claimed clinical utilityBiomarker models to predict disease progression in prostate cancer have a promising future, but at present, they have not fully justified their claimed clinical utilities, according to the authors of an independent review and analysis of the literature.
New PCa technologies bring hope, cautionI am more optimistic that we will find a way to treat those who truly need to be treated and follow those unlikely to die from their disease.